Jocasta Restructures α-Klotho Licensing Chain as JN-0413 Targets First-in-Human Trial in 2027

Age-related cognitive decline lacks therapies that are easy to administer and can directly improve brain function. Jocasta Neuroscience has now restructured the licensing framework for its α-klotho technology in an effort to move years of accumulated animal research toward the clinic. This step resolves development rights and commercial burdens; it does not yet validate efficacy.

Jocasta has signed a new agreement with the University of California, San Francisco (UCSF), securing exclusive rights to the university’s α-klotho-related intellectual property. The license covers neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, and also extends to mood and psychiatric disorders, neurological damage caused by disease or trauma, and the improvement of cognitive and motor function. Financial terms were not disclosed.

This is not a technology transfer starting from scratch. UNITY Biotechnology licensed the relevant patents and technology from UCSF in 2019 and, in 2021, licensed the α-klotho asset then known as UBX2089 to Jocasta. UNITY’s public filings show that the transaction included a $5 million upfront payment, as well as subsequent payments tied to development, approval, and sales progress. With the new agreement replacing and expanding the previous arrangement, Jocasta said it no longer owes milestone payments or royalties to UNITY, effectively consolidating the core rights directly between itself and UCSF.

Lead candidate JN-0413 is a proprietary synthetic α-klotho protein formulation administered by subcutaneous injection and remains at the preclinical stage. The company’s stated timeline is to submit an investigational new drug application in the fourth quarter of 2026 and begin a Phase 1 human trial around the first quarter of 2027. Whether the trial can start on schedule will still depend on preparations including manufacturing, toxicology, and regulatory review.

α-klotho is a protein produced naturally by the human body that declines with age, and both genetic and animal studies suggest an association with cognitive function. Peer-reviewed research cited by Jocasta showed that aged rhesus macaques given a single subcutaneous injection experienced improved working-memory performance within hours, with some effects lasting about six weeks. UNITY has also observed pro-cognitive activity from recombinant α-klotho in rodent and nonhuman primate models.

However, improved performance by healthy or aged animals on memory tasks cannot be directly equated with clinical benefit for patients with dementia. There are not yet human data for JN-0413 on pharmacokinetics, tolerability, appropriate dosing, or the effects of continued treatment. It is also unclear whether cognitive impairments caused by different etiologies will respond consistently to the same intervention.

The new license gives Jocasta a broader range of indications to choose from and removes some of the economic burden of the previous transaction, but the broad scope of the rights does not mean that development evidence is already available for all of these diseases. If the upcoming Phase 1 trial proceeds successfully, it must first answer the fundamental questions: whether subcutaneous α-klotho is safe in humans, whether it can achieve a measurable biological effect, and whether the durable signal seen in primate studies can be reproduced.